Zogenix Inc

NASDAQ:ZGNX  
25.97
-0.03 (-0.12%)
Products

Zogenix Announces U.S. FDA Acceptance For Priority Review Of Supplemental New Drug Application For Fintepla For Treatment Of Seizures Associated With Lennox-Gastaut Syndrome

Published: 12/01/2021 13:34 GMT
Zogenix Inc (ZGNX) - Zogenix Announces U.S. FDA Acceptance for Priority Review of Supplemental New Drug Application for Fintepla® (fenfluramine) for the Treatment of Seizures Associated With Lennox-gastaut Syndrome (lgs).
Zogenix Inc - FDA Granted Priority Review With a Prescription Drug User Fee Act Target Action Date of March 25, 2022.